1-8 of 8
Peter S. Hammerman
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Tumor Intrinsic Efficacy by SHP2 and RTK Inhibitors in KRAS-Mutant Cancers

Free
Huai-Xiang Hao, Hongyun Wang, Chen Liu, Steven Kovats, Roberto Velazquez, Hengyu Lu, Bhavesh Pant, Matthew Shirley, Matthew J. Meyer, Minying Pu, Joanne Lim, Michael Fleming, LeighAnn Alexander, Ali Farsidjani, Matthew J. LaMarche, Susan Moody, Serena J. Silver, Giordano Caponigro, Darrin D. Stuart, Tinya J. Abrams, Peter S. Hammerman, Juliet Williams, Jeffrey A. Engelman, Silvia Goldoni, Morvarid Mohseni
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2019) 18 (12): 2368–2380.
https://doi.org/10.1158/1535-7163.MCT-19-0170
Published: 02 December 2019
View article titled, Tumor Intrinsic Efficacy by SHP2 and RTK Inhibitors in KRAS-Mutant Cancers
Open the PDF for Tumor Intrinsic Efficacy by SHP2 and RTK Inhibitors in KRAS-Mutant Cancers in another window
Includes: Supplementary data
Journal Articles

Abstract A122: Molecular barcoding and single cell approaches to investigate drug tolerance in EGFRmut NSCLC

Free
Jennifer L. Cotton, Viveksagar KrishnamurthyRadhakrishna, Julie Chen, Michelle Piquet, Joel Wagner, Gaylor Boulay, Kathleen Sprouffske, Youngchul Song, Xiaoyan Li, Katja Schumacher, Raphael Thierry, Nathaniel D. Kirkpatrick, David A. Ruddy, Joshua Korn, Erick J. Morris, Peter S. Hammerman, Jeffrey A. Engelman, Matthew J. Niederst
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2019) 18 (12_Supplement): A122.
https://doi.org/10.1158/1535-7163.TARG-19-A122
Published: 01 December 2019
View article titled, Abstract A122: Molecular barcoding and single cell approaches to investigate drug tolerance in EGFRmut NSCLC
Journal Articles

SHP2 Inhibition Overcomes RTK-Mediated Pathway Reactivation in KRAS-Mutant Tumors Treated with MEK Inhibitors

Free
Hengyu Lu, Chen Liu, Roberto Velazquez, Hongyun Wang, Lukas Manuel Dunkl, Malika Kazic-Legueux, Anne Haberkorn, Eric Billy, Eusebio Manchado, Saskia M. Brachmann, Susan E. Moody, Jeffrey A. Engelman, Peter S. Hammerman, Giordano Caponigro, Morvarid Mohseni, Huai-Xiang Hao
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2019) 18 (7): 1323–1334.
https://doi.org/10.1158/1535-7163.MCT-18-0852
Published: 01 July 2019
View article titled, SHP2 Inhibition Overcomes RTK-Mediated Pathway Reactivation in KRAS-Mutant Tumors Treated with MEK Inhibitors
Open the PDF for SHP2 Inhibition Overcomes RTK-Mediated Pathway Reactivation in KRAS-Mutant Tumors Treated with MEK Inhibitors in another window
Includes: Supplementary data
Journal Articles

RAS–MAPK Reactivation Facilitates Acquired Resistance in FGFR1-Amplified Lung Cancer and Underlies a Rationale for Upfront FGFR–MEK Blockade

Free
Bruno Bockorny, Maria Rusan, Wankun Chen, Rachel G. Liao, Yvonne Li, Federica Piccioni, Jun Wang, Li Tan, Aaron R. Thorner, Tianxia Li, Yanxi Zhang, Changhong Miao, Therese Ovesen, Geoffrey I. Shapiro, David J. Kwiatkowski, Nathanael S. Gray, Matthew Meyerson, Peter S. Hammerman, Adam J. Bass
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2018) 17 (7): 1526–1539.
https://doi.org/10.1158/1535-7163.MCT-17-0464
Published: 01 July 2018
View article titled, RAS–MAPK Reactivation Facilitates Acquired Resistance in FGFR1-Amplified Lung Cancer and Underlies a Rationale for Upfront FGFR–MEK Blockade
Open the PDF for RAS–MAPK Reactivation Facilitates Acquired Resistance in FGFR1-Amplified Lung Cancer and Underlies a Rationale for Upfront FGFR–MEK Blockade in another window
Includes: Supplementary data
Journal Articles

Abstract B96: Adaptive resistance to therapeutic PD-1:PD-L1 blockade is mediated by upregulation of the TIM-3 immune checkpoint

Free
Esra A. Akbay, Shohei Koyama, Yvonne Y. Li, Grit S. Herter-Sprie, Kevin A. Buczkowski, William G. Richards, Leena Gandhi, Amanda J. Redig, Scott J. Rodig, Hajime Asahina, Robert E. Jones, Meghana M. Kulkarni, Peter E. Fecci, Bruce E. Johnson, Pasi A. Janne, Jeffrey A. Engelman, Sidharta P. Gangadharan, Daniel B. Costa, Gordon J. Freeman, Raphael Bueno, F. Stephen Hodi, Glenn Dranoff, Kwok-Kin Wong, Peter S. Hammerman
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2015) 14 (12_Supplement_2): B96.
https://doi.org/10.1158/1535-7163.TARG-15-B96
Published: 01 December 2015
View article titled, Abstract B96: Adaptive resistance to therapeutic PD-1:PD-L1 blockade is mediated by upregulation of the TIM-3 immune checkpoint
Journal Articles

Abstract B99: Immune profiling of NSCLC tumors and matching normal lung samples by multicolor flow cytometry

Free
Elena Ivanova, Robert E. Jones, Mark M. Awad, Mark A. Bittinger, Meghana M. Kulkarni, Shohei Koyama, Christina G. Almonte, Abigail A. Santos, Jessie M. English, Julianne Barlow, William G. Richards, Peter S. Hammerman, Scott J. Rodig, Raphael Bueno, Kwok-Kin Wong
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2015) 14 (12_Supplement_2): B99.
https://doi.org/10.1158/1535-7163.TARG-15-B99
Published: 01 December 2015
View article titled, Abstract B99: Immune profiling of NSCLC tumors and matching normal lung samples by multicolor flow cytometry
Journal Articles

NSCLC Driven by DDR2 Mutation Is Sensitive to Dasatinib and JQ1 Combination Therapy

Free
Chunxiao Xu, Kevin A. Buczkowski, Yanxi Zhang, Hajime Asahina, Ellen M. Beauchamp, Hideki Terai, Yvonne Y. Li, Matthew Meyerson, Kwok-kin Wong, Peter S. Hammerman
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2015) 14 (10): 2382–2389.
https://doi.org/10.1158/1535-7163.MCT-15-0077
Published: 05 October 2015
View article titled, NSCLC Driven by DDR2 Mutation Is Sensitive to Dasatinib and JQ1 Combination Therapy
Open the PDF for NSCLC Driven by DDR2 Mutation Is Sensitive to Dasatinib and JQ1 Combination Therapy in another window
Includes: Supplementary data
Journal Articles

Acquired Resistance to Dasatinib in Lung Cancer Cell Lines Conferred by DDR2 Gatekeeper Mutation and NF1 Loss

Free
Ellen M. Beauchamp, Brittany A. Woods, Austin M. Dulak, Li Tan, Chunxiao Xu, Nathanael S. Gray, Adam J. Bass, Kwok-kin Wong, Matthew Meyerson, Peter S. Hammerman
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2014) 13 (2): 475–482.
https://doi.org/10.1158/1535-7163.MCT-13-0817
Published: 09 February 2014
View article titled, Acquired Resistance to Dasatinib in Lung Cancer Cell Lines Conferred by DDR2 Gatekeeper Mutation and NF1 Loss
Open the PDF for Acquired Resistance to Dasatinib in Lung Cancer Cell Lines Conferred by DDR2 Gatekeeper Mutation and NF1 Loss in another window
Includes: Supplementary data